Canaccord lowered the firm’s price target on Evolent Health to $45 from $47 and keeps a Buy rating on the shares. The firm said they remain encouraged with Evolent’s performance and believe the company sits in a unique position to assist managed care in addressing rising medical costs trends with specialty care management offerings targeting cardiovascular, musculoskeletal, and oncology care.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVH: